Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

What happened: Orion Corporation and Qilu Pharma Europe entered an agreement to commercialise an intravenous pembrolizumab biosimilar in Europe. Orion Pharma gains exclusive rights to distribute, market and sell the product in Europe, with Qilu supplying it. Key numbers: Agreement announced 6 October 2026. Orion 2025 net sales EUR 1,890 million; about 4,000 employees. Why it matters: Orion Pharma said the deal expands its strategic partnership with Qilu and moves its division closer to long-term targets and strategic goals, aiming at broader access to affordable quality medicines.

Orion Corporation and Qilu Pharma Europe entered an agreement to commercialise an intravenous pembrolizumab biosimilar in Europe. Orion Pharma gains exclusive rights to distribute, market and sell the product in Europe, with Qilu supplying it.

Orion Pharma said the deal expands its strategic partnership with Qilu and moves its division closer to long-term targets and strategic goals, aiming at broader access to affordable quality medicines.